Recording, summary, and materials available from July 14 webinar.
The need for treatment of mental illness and substance use disorders continues to grow. The unrelenting burden, high costs of care, unmet demand, and gaps in efficacy all create a considerable opportunity for innovation. A new class of pharmaceuticals —psychedelic medicines— is among the emerging therapies and business models attracting attention. In more tightly linking psychotherapy and psychopharmaceutical approaches, these medicines offer the potential for significant impact. However, beyond the demonstration of effectiveness, the adoption of such treatments and the creation of broad access will also require disruption of existing business models, exploring new approaches to drug development, and confronting the historical context regarding psychedelics and society.
Experts who are working in this area joined us to explore questions related to bringing this class of therapies to market, including:
- How will these innovations integrate into the current ecosystem – augmentation versus disruption?
- What are the considerations regarding health equity?
- Beyond demonstrating efficacy, what are the key barriers to adoption?
- What are the implications for clinicians, drug developers, payers, and patients?
Joy Sun Cooper, MBA
Head of Commercialization and Patient Access,MAPS Public Benefit Corporation
Joseph del Moral
Co-Founder and CEO, Field Trip
John Krystal, MD
Chair and Chief of Psychiatry, Yale-New Haven Hospital
Neil Leibowitz, MD, JD
Chief Medical Officer, Beacon Health Options
Managing Director & Senior Partner, Boston Consulting Group
Mike Apkon, MD, PhD, MBA
President, Sand Street Advisors